The lectin pathway inhibitor, narsoplimab, which exerts its activity by blocking MASP-2, has been shown to prevent EC damage and thrombotic microangiopathy; recovery and survival was observed in all COVID-19 patients treated with narsoplimab (216). The gene discussed is MASP2; the disease is COVID-19.